Skip to content

Stoke Therapeutics, Inc. STOK Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$98.27M+32.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$210.7M+203%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$103.85M-61.6%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$31.73M-30.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
Nuvation Bio logo
Nuvation BioNUVB
$3.91M+107%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$1.89B+436%

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Stoke Therapeutics, Inc. (STOK) reported comprehensive income (loss), net of tax, attributable to parent of -$50.66M in Q1 2026.
How has Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 144.9% year-over-year, from $112.93M to -$50.66M.
What is the long-term trend for Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -48.2% compound annual growth rate (CAGR), from -$85.97M to -$6.19M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, combining net income with other comprehensive income items. It serves as a comprehensive measure of the company's total financial performance and wealth generation during a specific period. Investors use this to assess the overall impact of both operational results and external market factors on shareholder value.